3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Colorectal Neoplasms
14
Breast Neoplasms
12
Lung Neoplasms
10
Uterine Cervical Neoplasms
9
Neoplasms
8
Colonic Neoplasms
5
Hematopoietic and Lymphatic System Neoplasm
4
Prostatic Neoplasms
3
Papillomavirus Infections
3
Liver Neoplasms
3
Carcinoma, Hepatocellular
3
Rectal Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Patient Compliance
2
Carcinoma, Intraductal, Noninfiltrating
2
Tobacco Use
1
Smoking
1
Pyloric Stenosis, Hypertrophic
1
Psychological Well-Being
1
Overweight
1
Obesity
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Multiple Endocrine Neoplasia Type 1
1
Lymphoma
1
Liver Diseases
1
Hypertension
1
Hepatitis C
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Interventions
Cyclophosphamide
297
Rituximab
272
Etoposide
149
Filgrastim
142
fludarabine phosphate
120
Cytarabine
109
Vincristine
107
Melphalan
102
Radiotherapy
101
Doxorubicin
97
Peripheral Blood Stem Cell Transplantation
93
Methotrexate
91
fludarabine
86
Prednisone
86
Busulfan
86
Tacrolimus
66
Mycophenolic Acid
62
Granulocyte Colony-Stimulating Factor
60
Antilymphocyte Serum
58
Dexamethasone
57
Whole-Body Irradiation
55
Carmustine
54
Bortezomib
45
Cyclosporine
44
Lenalidomide
41
Methylprednisolone
40
sargramostim
39
Bendamustine Hydrochloride
37
ibritumomab tiuxetan
34
Ifosfamide
34
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoma
×
Patient Navigation
×
Clear all
NCT06063603
2025-09-18
ASCENT
Mayo Clinic
Phase NA
Completed
51 enrolled
8 charts